Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
10-7-2021

Inhibition of the NLRP3 inflammasome improves lifespan in
animal murine model of Hutchinson-Gilford Progeria
Alvaro González-Dominguez
Raúl Montañez
Beatriz Castejón-Vega
Jéssica Nuñez-Vasco
Débora Lendines-Cordero

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Authors
Alvaro González-Dominguez, Raúl Montañez, Beatriz Castejón-Vega, Jéssica Nuñez-Vasco, Débora
Lendines-Cordero, Chun Wang, Gabriel Mbalaviele, José M Navarro-Pando, Elísabet Alcocer-Gómez, and
Mario D Cordero

Report

Inhibition of the NLRP3 inflammasome
improves lifespan in animal murine model of
Hutchinson–Gilford Progeria
~ez1,† , Beatriz Castejo
n-Vega2,
l Montan
Alvaro Gonz
alez-Dominguez1,† , Rau
~ez-Vasco1 , Debora Lendines-Cordero1, Chun Wang3, Gabriel Mbalaviele3,
Jessica Nun
mez5 & Mario D Cordero1,*
Jose M Navarro-Pando4, Elısabet Alcocer-Go

Abstract
Inflammation is a hallmark of aging and accelerated aging
syndromes such as Hutchinson–Gilford progeria syndrome (HGPS).
In this study, we present evidence of increased expression of the
components of the NLRP3 inflammasome pathway in HGPS skin
fibroblasts, an outcome that was associated with morphological
changes of the nuclei of the cells. Lymphoblasts from HGPS
patients also showed increased basal levels of NLRP3 and caspase
1. Consistent with these results, the expression of caspase 1 and
Nlrp3, but not of the other inflammasome receptors was higher in
the heart and liver of Zmpste24 / mice, which phenocopy the
human disease. These data were further corroborated in
LmnaG609G/G609G mice, another HGPS animal model. We also
showed that pharmacological inhibition of the NLRP3 inflammasome by its selective inhibitor, MCC950, improved cellular phenotype, significantly extended the lifespan of progeroid animals, and
reduced inflammasome-dependent inflammation. These findings
suggest that inhibition of the NLRP3 inflammasome is a potential
therapeutic approach for the treatment of HGPS.
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Introduction
Aging is associated with progressive impairment of homeostasis at
the cell, tissue, and organismal level (L
opez-Otın et al, 2013). Aging

is also associated with inflammation, a process known as inflammaging during which key inflammatory pathways such as the NLRP3
inflammasome are activated (Franceschi et al, 2006).
The NLRP3 inflammasome is one of the most well-studied
inflammasomes in humans and mice (Afonina et al, 2017). It is a
multiprotein complex comprising NLRP3 itself as an intracellular
sensor, the adapter protein ASC, and the catalytic subunit, caspase
1. The NLRP3 inflammasome is activated by a range of danger and
stress signals (Afonina et al, 2017) some of which arise during aging
(Cordero et al, 2018). Consistent with this view, ablation of Nlrp3 in
mice has been shown to improve lifespan and healthspan by attenuating multiple age-related degenerative changes such as cardiac
aging, insulin sensitivity, bone loss, and ovarian aging (Youm et al,
2013; Marın-Aguilar et al, 2020; Navarro-Pando et al, 2021).
However, the role of the NLRP3 inflammasome has not been
assessed in genetic models of accelerated aging such as Hutchinson–
Gilford progeria syndrome (HGPS), a rare premature aging condition
in which a point mutation in the LMNA gene (c.1824C>T;
GGC>GCT; p.G608G) (Schreiber & Kennedy, 2013) causes the accumulation of aberrant lamin A precursor of lamin A at the nuclear
envelope, resulting in the disruption of the nuclear membrane architecture, abnormal gene transcription, and signal transduction. The
clinical phenotype is characterized by delayed loss of primary teeth,
alopecia, osteoporosis, abnormal skin pigmentation, accelerated
cardiovascular disease, growth impairment, lipodystrophy, dermal
abnormalities, and metabolic alterations (Lai & Wong, 2020).
Nuclear factor jB (NF-jB) mediates the secretion of high levels of
pro-inflammatory cytokines in the mouse HGPS model caused by
the absence of Zmpste24, the integral membrane zinc metalloprotease involved in the proteolytic processing of farnesylated
prelamin-A, the precursor of the nuclear scaffold protein lamin A
(Osorio et al, 2012). Accordingly, genetic and pharmacological
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inhibition of NF-jB signaling prevents age-associated features in
these animal models and extends their longevity (Osorio et al,
2012). Interestingly, NF-jB is a central mediator of NLRP3
inflammasome priming signals (Elliott & Sutterwala, 2015). In the
present work, we report that human skin fibroblasts and lymphoblasts from patients with HGPS and Zmpste24 / mice exhibited
increased activation of the NLRP3 inflammasome, a response that
was corroborated by LmnaG609G/G609G. In addition, we showed that
this alteration is detrimental as patients’ skin fibroblasts and
Zmpste24 / mice treated with MCC950, a specific inhibitor of
NLRP3, showed improved phenotype evidenced by the amelioration
of progeroid features (e.g., decreased inflammation and extended
longevity) compared to untreated Zmpste24 / mice.

Results
HGPS patients’ cells exhibit hyperactivated NLRP3 inflammasome
To evaluate the role of the NLRP3 inflammasome in progeria, we
examined the expression of the components of the NLRP3
inflammasome pathway in HGPS and control fibroblasts. THP1 cells
treated with LPS + ATP were used as positive control. Immunoblotting analysis showed higher expression of NLRP3 and capsase-1 in
HGPS fibroblasts (Fig 1A), data that were corroborated by
immunofluorescence (Fig 1B).
It is known that soluble circulating factors can induce cardiac
and metabolic damage and systemic inflammation (Libby et al,
2016). Furthermore, metabolic alterations have been observed in
animal models of HGPS with lipid accumulation (Mari~
no et al,
2008). To evaluate the response of the NLRP3 inflammasome
complex to metabolic alterations, we exposed HGPS lymphoblasts
and age- and passage-matched controls to cholesterol crystals and
uric acid, two well-known metabolic inducers of this inflammasome
(L
opez-Otın et al, 2013; Cordero et al, 2018). HGPS cells showed
increased basal levels of NLRP3 and caspase 1 protein expression
with a moderate increase after exposure to cholesterol crystals and
uric acid compared to control cells (Fig 1C). This response was
accompanied by increased IL-1b and IL-18 release in na€ıve condition
compared with control and similar release than control after cholesterol and uric acid treatment (Fig 1D).
Zmpste24-deficient mice exhibit hyperactivated NLRP3
inflammasome
To extend in vitro observations to an in vivo setting, we evaluated the inflammasome complex status in a murine model of
progeria. For this purpose, we used a mouse model in which the
absence of Zmpste24 metalloproteinase leads to a progeroid
phenotype similar to the human premature aging syndrome.
Examinations of basal levels of inflammasome components
revealed higher expression of Nlrp3, caspase 1 and IL-1b mRNAs,
and proteins in heart and liver tissues (Fig 1E and F and
Appendix Fig S1 and S2), but not in muscle (Fig EV1) of
Zmpste24 / mice compared to wild-type animals. Furthermore,
the NLRP3 inflammasome was also activated in the heart and
moderately in liver in the LaminG609G/G609G mouse model
(Fig EV2). These new findings reveal different effects of the
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inflammasomes in two genetic different models of HGPS, preliminary observations that will be further investigated.
Inhibition of the NLRP3 inflammasome improves the progeria
phenotype
To examine whether pharmacological inhibition of NLRP3 could be
an effective treatment in HGPS, we assessed the effect of MCC950
on mutant fibroblasts. Control and HGPS patients’ fibroblasts were
treated at two different concentrations of MCC950 (0.6 and 1.2 µM).
The results showed a statistically significant dose-dependent
increase in the growth rate of patient fibroblasts (Fig 2A). Western
blot analyses showed that MCC950 reduced progerin signals in
HGPS cells, responses that were associated with reduced NLRP3,
caspase 1, and IL-1b expression (Fig 2B, Appendix Fig S3 and S4).
Interestingly, inhibition of the NLRP3 inflammasome expression
and activity by MCC950 reduced the frequency of abnormal nuclear
morphology in both control and HGPS fibroblasts (Fig 2C–E).
Inhibition of the NLRP3 inflammasome extends the longevity of
Zmpste24-deficient mice
We explored in vivo effects of pharmacological inhibition of NLRP3
in Zmpste24 / mice. MCC950 was administered by i.p. route at
20 mg/kg daily. We found that treatment with MCC950 resulted in a
significantly extended longevity of Zmpste24 / mice, with a mean
increase lifespan of 19.2% (P < 0.01), an improvement in body
weight from 14.7  0.7 to 18.6  0.7 g (P < 0.001), and a reduction
in IL-1b production (Fig 2F–H).

Discussion
Genetic deletion of Nlrp3 in mice has been shown to improve lifespan and healthspan by attenuating multiple age-related degenerative
changes such as cardiac aging, insulin sensitivity with glycemic
control, bone loss, cognitive function, and motor performance
(Youm et al, 2013; Cordero et al, 2018; Marın-Aguilar et al, 2020).
Cardiovascular diseases are reduced in NLRP3 deficient mice as
NLRP3-assembled inflammasome is up-regulated in atherosclerosis,
myocardial infarction, ischemic heart disease, chronic heart failure,
and hypertension (Marın-Aguilar et al, 2020). Cardiovascular
diseases have also been shown to be accelerated in HGPS patients
and progerin. Furthermore, the abnormal form of prelamin-A has
also been shown to induce atherosclerosis and cardiac electrophysiological alterations (Hamczyk et al, 2018) and exogenously
expressed progerin was shown to increase inflammation. Finally, a
significant correlation was observed between inflammation and
ZMPSTE24, and abnormal lamin A/C expression associated with
progerin levels was observed in cardiovascular patients (Bidault
et al, 2020; Messner et al, 2020). These changes altered the
morphology of the nucleus, and progerin has been shown to induce
IL-1b (Bidault et al, 2020). Our results suggest that progerin was
responsible for the activation of the NLRP3 inflammasome complex,
which was associated with alterations of nuclear morphology. On
the other hand, the AIM2 inflammasome has been shown to be activated after pharmacological alterations of the nuclear envelope
integrity compatible with laminopathies (Di Micco et al, 2016).
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Figure 1. NLRP3 signaling is associated with HGPS.
A Western blot analysis with representative blot including lamin A/C, NLRP3, caspase 1, and actin levels in skin fibroblasts from patients with HGPS, n = 2 controls and
2 patients. Positive control correspond to THP1 cells stimulated with LPS+ATP.
B Immunofluorescence (IF) visualization of NLRP3 (green) and nuclei (blue) in skin fibroblasts from a representative patient and control. Scale bar: 30 µm.
C Protein expression of NLRP3 and caspase 1 in lymphoblasts from control and one patient after stimulation with uric acid and cholesterol crystal.
D IL-1b and IL-18 medium release from lymphoblasts which were assessed after a 24-h incubation with uric acid and cholesterol. ***P < 0.001, **P < 0.005, *
treatment vs no treatment; aaaP < 0.001; aaP < 0.01 control cells vs patient cells.
E Western blot analysis with representative blot including NLRP3, caspase 1, IL-1b and actin levels in heart and liver tissues from wild-type and Zmpste24 / mice.
F NLRP3 and caspase 1 transcript expression levels were determined in heart and liver tissues by real-time quantitative RT–PCR. n = 5 for Zmpste24+/+ and n = 5 for
Zmpste24 / groups respectively. ***P < 0.001, **P < 0.005, wild-type vs Zmpste24 / mice. Data are showed means  SD, n = 4 mice per group.
Data information: Results are presented as the mean  SD of three independent experiments. One-way ANOVA test was used for statistical analysis
Source data are available online for this figure.
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Figure 2. NLRP3 inhibition by MCC950 ameliorates skin fibroblasts and Zmpste24-deficient mice progeroid phenotypes.
Cell growth (lower subpanel left patient 1 and right patient 2) and morphological aspect (upper subpanel) with MCC950 determined in healthy and representative
HGPS fibroblasts. **P < 0.01, *P < 0.05 patient cells no treatment vs treatment. Results are presented as the mean  SD of three independent experiments.
B
Western blot analysis with representative blots including lamin A/C, NLRP3, IL-1b, and actin levels in skin fibroblasts from control and HGPS patient after 48 h of
vehicle and MCC950 treatment.
C–E Representative fluorescence images of HGPS and control fibroblasts to evaluate the effect of the MCC950 in the nuclear morphology (D) and NLRP3 expression (E).
Scale bar: 30 µm. Results are presented as the mean  SD of three independent experiments. ***P < 0.01 patient vs control cells, aaaP < 0.01 patient cells no
treatment vs treatment. One-way ANOVA test was used for statistical analysis.
F
Kaplan–Meier graph showing a significant increase in the maximum lifespan in WT mice compared with Zmpste24 / mice. N = 7 per group.
G
Body weights evolution of the groups over time. Data are showed means  SD, n = 6 mice per group.
H
Analysis of serum concentrations of IL-1b measured by ELISA. N = 6 per group. Data are shown as means  SD. ***P < 0.001, wild-type vs Zmpste24 / mice;
aaa
P < 0.001; vehicle vs MCC950.
A

Source data are available online for this figure.
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Thus, it is tempting to speculate that inflammasomes contribute to
increased aging observed in progeroid syndromes.
Efforts have been launched to find specific pharmacological inhibitors of NLRP3. While several of these inhibitors have been shown
to have a specific direct action on NLRP3, others have been shown
indirect inhibitory effects (Zahid et al, 2019). MCC950 and analogs
are selective small molecule inhibitors of the NLRP3 inflammasome,
with remarkable therapeutic potential in human diseases. A few
anti-inflammatory strategies for the treatment of HGPS have been
poorly explored (Lai & Wong, 2020) though some of the drugs that
treat HGPS such as metformin, resveratrol, rapamycin, quercetin or
spermidine indirectly inhibit inflammatory pathways such as the
NLRP3 inflammasome (Cordero et al, 2018). In the current study,
we provided evidence showing that the NLRP3 inflammasome
complex is an important determinant of HGPS in human cells and
mice. We showed that the specific expression of NLRP3 and other
components of the complex rapidly increased in the skin fibroblasts
from patients and in specific tissues associated with the progeroid
phenotype and associated with inflammation such as heart or liver
(Osorio et al, 2012; Schreiber & Kennedy, 2013; Lai & Wong, 2020).
Moreover, we found continuous activation of the NLRP3 inflammasome in immune cells such as lymphocytes from patients. Finally,
pharmacological inhibition of the NLRP3 inflammasome by MCC950
improved cell survival and morphology, reduced inflammation, and
resulted in extended longevity of HGPS mice. Interestingly, we
found that MCC950 treatment reduced the protein levels of NLRP3
in HGPS. These data could not be associated with the described
mechanism of MCC950, which binds to NLRP3 and blocks its ability
to hydrolyze ATP, and thus prevents it from maintaining its active
structural conformation, and inhibiting NLRP3-induced ASC
oligomerization and reducing cleavage of caspase 1 (Coll et al,
2019; Tapia-Abell
an et al, 2019). However, previous data have
showed similar effect of MCC950 about the inhibition of NLRP3
protein (Mridha et al, 2017; Gordon et al, 2018). These data could
show the effect of MCC950 on the priming step of NLRP3 activation.
Therefore, this HGPS treatment strategy, focused on the inhibition
of NLRP3 inflammasome complex, could constitute an alternative
therapy to slow down disease progression in patients with progeria.

Materials and Methods
Reagents
Trypsin was purchased from Sigma Chemical Co., (St. Louis,
Missouri). Anti-actin monoclonal antibody from Calbiochem-Merck
Chemicals Ltd. (Nottingham, UK). Lamin A/C, NLRP3 and caspase
1 were obtained from Cell Signaling Technology. NLRP3 inhibitors
MCC950 was obtained from Sigma-Aldrich (Saint Louis, USA). A
cocktail of protease inhibitors (complete cocktail) was purchased
from Boehringer Mannheim (Indianapolis, IN). Grace’s insect
medium was purchased from Gibco. The Immun Star HRP substrate
kit was from Bio-Rad Laboratories Inc. (Hercules, CA).
Fibroblast culture
All fibroblasts from patients with HGPS were obtained from The
Progeria Research Foundation Cell and Tissue Bank (http://www.
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progeriaresearch.org). An informed consent was obtained from all
human subjects, and the experiments were done conformed to the
WMA Declaration of Helsinki and to the principles set out in the
Department of Health and Human Services Belmont Report. The
following fibroblasts were used: HGADFN367 (3-year-old male) and
HGADFN155 (1.2-year-old female). Control fibroblasts was used the
HGADFN368 (37-year-old female), mother of the HGADFN367.
Fibroblasts were cultured in high glucose Dulbecco’s modified
media (; Gibco, Invitrogen, Eugene, OR, USA) supplemented with
15% fetal bovine serum (FBS; Gibco, Invitrogen, Eugene, OR, USA),
1% GlutaMAX (Thermo Fisher) and antibiotics (Sigma Chemical
Co., St. Louis, MO, USA). Cells were incubated at 37°C in a 5% CO2
atmosphere. The medium was changed every 2 days to avoid
changes in pH.
We also used the following lymphoblasts: HGALBV009 (5.1-yearold male) and HGALBV021 (father of the proband, 37-year-old).
Lymphoblasts were cultured in RPMI-1640 (Gibco, Invitrogen,
Eugene, OR, USA) supplemented with 15% FBS (Gibco, Invitrogen,
Eugene, OR, USA), and antibiotics (Sigma Chemical Co., St. Louis,
MO, USA). Cells were incubated at 37°C in a 5% CO2 atmosphere.
As a positive control of the NLRP3 inflammasome complex activation, we used THP1 cells primed with 200 ng/ml ultrapure LPS
for 4 h, followed by stimulation with PBS (mock), 5 mM ATP
(30 min).
Real-time quantitative PCR
The expression of the NLRP3 and caspase 1 genes was analyzed by
SYBR Green quantitative PCR of mRNA extracted from GCs according to the previously described methodology (Marın-Aguilar et al,
2020). Briefly, total cellular RNA was purified from the cells by the
Trisure method (Bioline, London, UK). RNA concentration was
determined spectrophotometrically. RNA samples were subsequently reverse transcribed to cDNA using the QuantiTect Reverse
Transcription Kit (Qiagen, Hilden, Germany). PCR amplifications
were conducted with primers targeting NLRP3 (NM_004895.4) and
beta-actin, used as an internal control. Thermal cycling conditions
used were denaturation at 95°C for 20 s, 40 cycles of priming at
54°C for 20 s, and elongation at 72°C for 20 s. All reactions were
performed in duplicate, and reaction mixes without RNA were used
as negative controls in each run. Absence of contaminating genomic
DNA was confirmed by setting up control reactions with RNA that
had not been reverse transcribed. Fold changes in the expression of
genes of interest were calculated using the DDCt method.
Western blotting
Whole cellular lysate from fibroblasts was prepared by gentle shaking with a buffer containing 0.9% NaCl, 20 mM Tris-HCl, pH 7.6,
0.1% Triton X-100, 1 mM phenylmethylsulfonylfluoride and 0.01%
leupeptin. The protein content was determined by the Bradford
method. Electrophoresis was carried out in a 10–15% acrylamide
SDS–PAGE, and proteins were transferred to Immobilon membranes
(Amersham Pharmacia, Piscataway, NJ). Next, membranes were
washed with PBS, blocked over night at 4°C, and incubated with the
respective primary antibody solution (1:1,000). Membranes were
then probed with their respective secondary antibody (1:2,500).
Immunolabeled proteins were detected by chemiluminescence
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The paper explained
Problem
Progeria is a very rare disease associated to a fatal, pediatric autosomal dominant premature aging disease caused by a mutation in the
LMNA gene. This mutation results in accumulation of a high level of
an aberrant protein, termed progerin, which is accumulated in many
tissues and is responsible for the diverse pathophysiological events
and rapid degeneration. Children die predominantly from premature
atherosclerotic cardiovascular disease. However, no specific therapeutic
target has been defined.
Results
Our findings show NLRP3 inflammasome complex activation in cells
from patients. Skin fibroblasts and lymphoblasts from HGPS syndrome
showed high levels of NLRP3, caspase 1, and IL-1b. Similar findings
were observed in HGPS animal models in heart and liver. Interestingly,
pharmacological inhibition of MCC950 using MCC950 increased
survival and bodyweight and reduced IL-1b levels of animal model of
HGPS.
Impact
Our data suggest an essential role for NLRP3 signaling in the pathogenesis of HGPS and reveal a promising therapeutic target for progeria treatment.

method (Immun Star HRP substrate kit, Bio-Rad Laboratories Inc.,
Hercules, CA). Western blot images were quantified using ImageJ
software.
NLRP3 immunofluorescence
NLRP3 distribution in cytosol was assessed by immunofluorescence
techniques using antibodies against NLRP3 and DAPI as a marker of
the nuclei.
Nuclear morphology
For nuclear deformation cell quantification, nuclei were stained with
DAPI. After staining, abnormal nuclei were counted in randomly
selected fields (minimum one hundred cells per case) and expressed
as percentages of total cells counted. Counting of cells with nuclear
deformation was performed by three independent observers.

for the use of laboratory animals in chronic experiments (RD 53/
2013 on the care of experimental animals). All experiments were
approved by the local institutional animal care committee. For all
experiments, only male mice were used. Mutant mice deficient in
Zmpste24 metalloproteinase and LmnaG609G/G609G have been
described previously (Osorio et al, 2012). All groups had ad libitum
access to their prescribed diet and water throughout the whole
study. Body weight was monitored weekly. Animal rooms were
maintained at 20–22°C with 30–70% relative humidity. As positive
control, we used a gain of function NLRP3 mutant associated with
neonatal onset multisystem inflammatory disease in mice (Bonar
et al, 2012).
For all experiments with NLRP3 inhibitors, Zmpste24+/+ (wild
type) and Zmpste24 / were maintained on a regular 12 h light/dark cycle at 20–22°C. Treatments were started at 1 month of age
after randomization into three groups (wild-type vehicle,
Zmpste24 / vehicle, and Zmpste24 / MCC950). These groups
correspond to the following treatment: (i) standard diet with i.p
vehicle (saline) treatment (vehicle groups) from Teklad Global 14%
Protein Rodent Maintenance Diet, Harlan Laboratories (carbohydrate:protein:fat ratio of 48:14:4 percent of kcal) and (ii) standard
diet with MCC950 treatment (MCC950 group). MCC950 was administered 20 mg/kg daily by i.p. route. All groups had ad libitum
access to their prescribed diet and water throughout the study. Individuals were monitored daily and weighed monthly but were otherwise left undisturbed until they died. Survival was assessed using
male mice, and all animals were dead by the time of this report.
Kaplan–Meier survival curves were constructed using known birth
and death dates, and differences between groups were evaluated
using the log-rank test. A separate group of male mice were sacrificed at age 4 months to study (Western blots).
Statistical analysis
Data in the figures are shown as mean  SD. Data between different
groups were analyzed statistically by using ANOVA on ranks with
Sigma plot and Sigma Stat statistical software (SPSS for Windows,
19, 2010, SPSS Inc. Chicago, IL, USA). Normality was assessed with
the Kolmogorov–Smirnov test. In case of unequal variances,
Welch’s correction was applied. For cell-culture studies, Student’s ttest was used for data analyses. A value of P < 0.05 was considered
significant. In animal studies, the experiments were done after
encoding the name of the groups.

Proliferation assay
@Fibroblasts were seeded in 12-well plates. One hundred thousand
fibroblasts were cultured with or without the MCC950 at two different
concentrations (0.6 and 1.2 µM) for 24, 48, and 120 h. To measure
proliferation rate, fibroblasts was seeded and after treatment, cells
were harvested and quantified by using a TC10TM Automated Cell
Counter (Bio-Rad). Cell viability was assessed by trypan blue exclusion. Proliferation rate was calculated by total cell number. Results
are expressed as mean  SD of two independent assays.

Data availability
This study includes no data deposited in external repositories.
Expanded View for this article is available online.
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